Lopinavir–ritonavir in severe COVID-19 Research Highlights Published on 2020-04-092022-10-05 Journal: Nature Medicine [Category] SARS, 임상, 치료법, [키워드] severe COVID-19 [DOI] 10.1038/s41591-020-0849-9 [Article Type] Research Highlights
Antiviral therapy in management of COVID-19: a systematic review on current evidenceReview Article Published on 2020-04-062022-10-27 Journal: Archives of Academic Emergency Medicine [Category] COVID-19, [키워드] addition antiviral agent antiviral therapy can be used clinical trial coronavirus COVID-19 database determine Efficacy Epidemics evaluate Evidence identify independent international organization management MERS-CoV Middle East organization pandemic Patient performed potential treatment option regimen reported researcher respiratory SARS-CoV severe COVID-19 standard treatment systematic review therapy Treatment was performed Web of Science WHO World Health Organization PMC 바로가기 [Article Type] Review Article
Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside WuhanResearch Letter Published on 2020-03-182022-11-01 Journal: Critical Care [Category] COVID-19, MERS, SARS, [키워드] COVID-2019 disease severity Host host susceptibility risk Risk factors severe COVID-19 susceptibility Wuhan [DOI] 10.1186/s13054-020-2833-7 PMC 바로가기 [Article Type] Research Letter
Coagulation profile in severe COVID-19 patients: what do we know so far?Commentary Published on 2020-01-012022-10-29 Journal: Revista Brasileira de Terapia Intensiva [Category] Coronavirus, SARS, [키워드] severe COVID-19 [DOI] 10.5935/0103-507X.20200031 PMC 바로가기 [Article Type] Commentary
COVID-19 prognosis: what we know of the significance and prognostic value of liver-related laboratory parameters in SARS-CoV-2 infectionMeta-Analysis Published on 2020-01-012022-10-31 Journal: Gastroenterology and Hepatology From Bed to Bench [Category] COVID-19, [키워드] alanine aminotransferase albumin ALT alteration Aminotransferase Aspartate aminotransferase AST Atypical Bili Bilirubin clinician contribute correlation COVID-19 COVID-19 patients death evaluate Health information Injury interval laboratory parameter liver Liver injury mean difference Meta-analysis Non-pulmonary non-severe patient organ outcome parameter Pneumonia primary symptom Prognosis Prognostic value progression representing resulting SARS-COV-2 infection scrutiny Severe case severe COVID-19 severe disease significantly lower the disease total bilirubin was performed while β-coronavirus PMC 바로가기 [Article Type] Meta-Analysis
Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China중국 저장성 COVID-19 환자의 임상적 특성 및 혈장 항체가Article Published on 2020-01-012022-09-12 Journal: Journal of Zhejiang University. Science. B [Category] MERS, 진단, [키워드] acute respiratory syndrome affected age anti-viral drug antibody Antibody titer Berry caused Characteristics China clinical Clinical characteristics common cold Convalescent patients convalescent plasma coronavirus Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 critically ill patients Donor effective Fatality rate female gastroenteritis Human humans IgG IgM immunization Immunoglobulin G improve clinical outcome increase Infection Infectious disease male Mild Neutralizing Neutralizing antibody titer offer patients with COVID-19 pilot study plasma antibody Pneumonia progression report reported SARS-CoV-2 severe COVID-19 severely ill patient shown the disease therapeutic efficacy therapeutic strategy therapy treating COVID-19 upper respiratory tract Vaccine Viremia WHO World Health Organization Zhejiang [DOI] 10.1631/jzus.B2000593 PMC 바로가기 [Article Type] Article
Increased inflammatory markers correlate with liver damage and predict severe COVID-19: a systematic review and meta-analysisSystematic Review Published on 2020-01-012022-10-31 Journal: Gastroenterology and Hepatology From Bed to Bench [Category] COVID-19, [키워드] 95% CI 95% CIs 95% confidence interval Analysis article calculated Cochrane Library coronavirus COVID-19 COVID-19 outbreak CRP database demonstrated determine effect size elevated Evidence form Health heterogeneity IL-6 IL-6 level increase in Increased increased risk Inflammation Inflammatory Inflammatory marker inflammatory markers ISI Liver damage mechanisms Meta-analysis Mild mild cases Patient patients with COVID-19 predict random effect reducing searched severe COVID-19 Severe infection Significant significantly higher SMD standardized mean difference systematic review the disease TNFα TNFα Web of Science PMC 바로가기 [Article Type] Systematic Review
Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled” trial (TOCIBRAS)"중등도에서 중증의 COVID-19 환자에 대한 토실리주맙: 공개 라벨 다기관 무작위 통제" 시험(TOCIBRAS)의 근거 및 설계Original Article Published on 2020-01-012022-08-13 Journal: Revista Brasileira de Terapia Intensiva [Category] 임상, [키워드] 7-point ordinal scale adjusted age and sex alleviate Analysis anti-inflammatory therapies Anti-inflammatory therapy applied approved Brazil C reactive protein Clinical outcome clinical outcomes clinical status combating consequence Coronavírus COVID-19 COVID-19 patient COVID-19 patients criteria D-dimer disease severity dissemination enrolment ethical committee Ethics ferritin IMPROVE inflammatory cascade inflammatory mediator Inflammatory response inhibiting institutional review board institutional review boards interleukin-6 International Lactate lactate dehydrogenase limit Local mediator moderate to severe multicentre National Odds ratio Open-label ordinal logistic regression Ordinal Scale outcome patients patients with COVID-19 patients with moderate primary endpoint Pro-inflammatory marker pro-inflammatory markers protocol Randomized Randomized controlled trial rationale required severe COVID-19 severity Standard of care Stratification Study protocol the disease The TOCIBRAS protocol TOCIBRAS Tocilizumab Tocilizumabe Trial trial testing variable [DOI] 10.5935/0103-507X.20200060 PMC 바로가기 [Article Type] Original Article